The JRKL Knockout HAP1 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal cell population designed for targeted disruption of the human JRKL gene. This loss-of-function model enables researchers to dissect the biological roles of JRKL in a controlled genetic background. The polyclonal format captures the natural allelic diversity resulting from CRISPR-based editing, providing a robust system for population-level assays and minimizing biases that can arise from single-cell cloning. By eliminating JRKL protein expression, these cells serve as an essential tool for investigating gene function in cancer-related processes.
The host HAP1 cell line is a near-haploid human cell line originally derived from the chronic myelogenous leukemia (CML) KBM-7 line. Its near-haploid karyotype, which retains only one copy of most chromosomes including Chromosome 11, greatly simplifies gene targeting and phenotypic analyses. This characteristic makes HAP1 a workhorse for haploid genetic screens, allowing unambiguous assignment of gene-trait relationships. Additionally, the CML origin positions HAP1 as a relevant system for leukemia research, enabling studies of oncogenic signaling and therapeutic targets.
JRKL is predicted to encode a DNA-binding protein that may contribute to transcriptional regulatory networks, although its molecular functions are still poorly characterized. The protein is hypothesized to play a role in cellular differentiation, potentially through interactions with chromatin or transcriptional co-regulators. However, no upstream regulators, downstream target genes, or protein interaction partners have been definitively identified. Preliminary evidence hints at a link to cancer biology, but the mechanistic underpinnings remain unknown, underscoring the need for functional models to define its biological significance.
In the context of HAP1 cells, JRKL knockout provides a versatile platform for functional studies, leveraging the host??s near-haploid genome and CML lineage. The near-haploid state reduces redundancy, enhancing the detectability of phenotypic changes upon gene disruption. The polyclonal knockout population allows immediate application in population-based assays without the delay of clonal isolation, facilitating rapid screening of cellular phenotypes. This model is particularly suited for evaluating how JRKL loss affects proliferation, differentiation, and drug sensitivity in a leukemia-relevant cellular environment, potentially revealing novel vulnerabilities.
This knockout product supports a wide range of research applications, including functional genomics to annotate JRKL??s cellular role, drug target discovery through viability and pathway modulation assays, and genetic screens to identify synthetic lethal interactors. Standard validation assays include western blotting to confirm protein knockdown, RT-qPCR for transcript-level analysis, RNA-seq for global expression profiling, and cell viability assays to quantify phenotypic outcomes. The polyclonal nature enhances suitability for high-throughput and pooled library screens. For technical support and ordering information, please contact Ascent Research.
